HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a price target of $51. This reaffirmation of the stock's potential could influence investor sentiment and the stock's short-term performance.
November 28, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus Therapeutics has been given a reiterated Buy rating and a maintained price target of $51 by HC Wainwright & Co. analyst Ed Arce, which could positively impact the stock's short-term performance.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor perception and stock prices. The reiteration of a Buy rating and a price target that suggests a positive outlook for the stock is likely to instill confidence among investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100